mash

Documents about mash

• Resmiterom Efficacy & Safety in Patients With MASH#874969ClinicalTrials.gov
• Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH#1263105ClinicalTrials.gov
• Global Research Initiative for Patients Screening on MASH#451565ClinicalTrials.gov
• A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH#1349886ClinicalTrials.gov
• Study of Resmetirom in Children and Adolescents With MASH#1293434ClinicalTrials.gov
• Resmetirom in Patients With MASH and HFpEF#1364579ClinicalTrials.gov
• <b>Metabolic succinylation prevents hepatocyte cuproptosis to suppress MASH</b>#1440958Figshare
• Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)#1443625ClinicalTrials.gov
• Nutrition Intervention Combined With Resmetirom for MASH#858567ClinicalTrials.gov
• Influence of Moisture Content on Some Physical Properties of Pineapple Pomace Based Mash#289871University of Ibadan Institutional Repository
• Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH#851599ClinicalTrials.gov
• The Metaphysics of Mash‐Ups#698395PhilArchive
• A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)#1351969ClinicalTrials.gov
• A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis#1410603ClinicalTrials.gov
• A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)#826148ClinicalTrials.gov
• Study of TGM-312-SC01 in Healthy Participants and Adults With MASH#1096426ClinicalTrials.gov
• System-Level Considerations for MASH Assessment#388564NCBI Bookshelf
• A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH#889805ClinicalTrials.gov
• A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)#895892ClinicalTrials.gov
• A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population#1432613ClinicalTrials.gov
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition#1263094ClinicalTrials.gov
• Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis#1246306ClinicalTrials.gov
• To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH#1294791ClinicalTrials.gov
• Thermoacoustic Method for Estimating Liver Fat Fraction#991699ClinicalTrials.gov
• A 1-1 MASH 2-D Vernier Time-to-Digital Converter with 2nd-order noise shaping#385055Lund University Publications
• A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH#1048061ClinicalTrials.gov
• Handbook of Family Medicine#1193265Open Library
• ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)#807011ClinicalTrials.gov
• Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM#1497768ClinicalTrials.gov
• A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database#1045347ClinicalTrials.gov
• A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)#1408884ClinicalTrials.gov
• A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH#888266ClinicalTrials.gov
• Metabolic Dysfunction-Associated Steatohepatitis (MASH) GeoMx and COMET Dataset#211387KU Leuven RDR Dataverse OAI Archive
• Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study#1421086ClinicalTrials.gov
• A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)#1409366ClinicalTrials.gov
• Pharmacological treatment of MASH#1148616Springer Nature OA
• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)#889606ClinicalTrials.gov
• Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)#1320756ClinicalTrials.gov
• Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients#1350560ClinicalTrials.gov
• Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial#1261940ClinicalTrials.gov
• Mitochondrial dysfunction and lipid droplet dynamics in MASH: HSD17B13 as a therapeutic target.#433992NCBI PubMed Central
• Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)#1337750ClinicalTrials.gov
• Plasma-targeted proteomic and lipidomic profiling of MASLD, MASH, and hepatitis C virus infection.#193728NCBI PubMed Central
• Signature gene expression model for quantitative evaluation of MASH-like liver injury in mice.#280898NCBI PubMed Central
• Clinical Classification of MAFLD Based Liver Biopsy#290888ClinicalTrials.gov
• SELECTIVE MTOR INHIBITION VIA FLCN DRIVES TFE3-DEPENDENT VLDL-TG SECRETION AND PROTECTS FROM MAFLD/MASH#929177ScholarlyCommons
• Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)#1197067ClinicalTrials.gov
• Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)#802659ClinicalTrials.gov
• Differential candidate characteristics associated with increasing ALD and MASH among liver transplant listings in the US.#148289NCBI PubMed Central
• The "Direct Structural Disruption" Hypothesis: Bacteroides fragilis Toxin as a Potentiating Cofactor in MASH Pathogenesis.#232452NCBI PubMed Central